Aries Wealth Management’s TScan Therapeutics TCRX Stock Holding History

Aries Wealth Management’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.8K	Hold	10,000	–	–	﹤0.01%	241
2026 Q1	$10.1K	Hold	10,000	–	–	﹤0.01%	233
2025 Q4	$10K	Hold	10,000	–	–	﹤0.01%	233
2025 Q3	$18.2K	Hold	10,000	–	–	﹤0.01%	231
2025 Q2	$14.5K	Hold	10,000	–	–	﹤0.01%	217
2025 Q1	$13.8K	Hold	10,000	–	–	﹤0.01%	223
2024 Q4	$30.4K	Hold	10,000	–	–	0.01%	216
2024 Q3	$49.8K	Hold	10,000	–	–	0.01%	225
2024 Q2	$58.5K	Hold	10,000	–	–	0.02%	200
2024 Q1	$79.4K	Hold	10,000	–	–	0.03%	204
2023 Q4	$58.3K	Hold	10,000	–	–	0.02%	195
2023 Q3	$35.3K	Buy	+10,000	New	+$23.3K	0.01%	194

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Aries Wealth Management's TCRX Position: Q2 2026 in Review

Aries Wealth Management held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 10,000 shares worth $9.8K. The position accounts for ﹤0.01% of the portfolio, ranked #241.

Aries Wealth Management first reported a position in TCRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $79.4K in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Aries Wealth Management held 10,000 shares of TScan Therapeutics worth $9.8K as of Q2 2026.
Aries Wealth Management left its TScan Therapeutics share count unchanged in Q2 2026.
TScan Therapeutics made up ﹤0.01% of Aries Wealth Management's portfolio in Q2 2026, its #241 holding.
Aries Wealth Management first reported a position in TScan Therapeutics in Q3 2023 and has held it in 12 quarters since.
Aries Wealth Management's TScan Therapeutics position peaked at $79.4K in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Aries Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.